Skip to main content

Deciphering crypto sentiment: Inside Crypto Fear & Greed index

To keep you updated, we send DeCrypt Weekly Update to your mailbox. In case, you wish to Unsubscribe Click Here
Powered by
DeCrypt Weekly Update

DeCrypt Weekly Update

Sat, Mar 30, 2024 | 11:57 AM IST
Deciphering crypto sentiment: Inside the crypto Fear and Greed Index

Hello Reader,

Investors are often grappled with a crucial question - is the market ripe for opportunity or is it on the precipice of a downturn? To determine this, one of the pieces of the puzzle is the 'Crypto Fear and Greed Index'. This nifty tool is an investor behavioral barometer that measures market sentiment, giving investors a glimpse into the collective emotions of crypto investors. This barometer operates on a scale of 0 to 100, with 0 signifying extreme fear and 100 indicating extreme greed.

The index analyzes various data points, including volatility, social media buzz, market momentum, and even Bitcoin 's dominance within the crypto landscape. By crunching this data, it assigns a score that indicates the overall mood - are investors panicking and selling off (extreme fear), or are they euphoric and piling in (extreme greed)? Read More
Parth Chaturvedi
About Parth ChaturvediInvestments Lead, CoinSwitch Ventures
CRYPTO TOP GAINERS
As on Mar 30, 2024 11:44 AM
Name LTP Vol (24h, Cr.) M.Cap (Cr.) Circ. Supply (Cr.)
cat in a dogs world 0.57195.27% 882 5,053 8,888.89
dogwifhat 38022.91% 7,081 38,234 99.89
Degen (Base) 2.4622.75% 503 3,091 1,248.16
Raydium 19621.25% 1,087 5,095 25.98
Jupiter 12719.79% 2,673 17,162 135.00
Nosana 39717.78% 24.21 3,311 8.34
Coq Inu 0.0015.72% 222 2,908 69,42,000.00
WEEKLY TOP NEWS
Memes, Pumps, Blunders: Absurd crypto spectacles make a comebackMemes, Pumps, Blunders: Absurd crypto spectacles make a comeback
It was another token that kept coming up in the conversations: a newer cryptocurrency best known for its logo featuring an image of a dog wearing a knit hat. The billionaire Michael Novogratz, chief executive officer of Galaxy Digital, jokingly lamented that he doesn't have a position in the coin called dogwifhat.
Should you invest in meme coins? Crypto educator Gopal Dutt Vashisht guides you through the decision to invest in Crypto Academy episode 3Should you invest in meme coins? Crypto educator Gopal Dutt Vashisht guides you through the decision to invest in Crypto Academy episode 3
Meme coin trading surges on Indian exchanges, sparking investor interest. Vashisht advises cautious investment due to risks. Diversify portfolios with meme coins wisely for balanced returns. Crypto Academy offers insights on meme coin dynamics and investments.
A Message From Mudrex
Mudrex presents ETMarkets Emerging Investment Opportunities
Amrit Kaal for Investors: Looking beyond equities" Embark on your investment journey with confidence as we delve into the diverse world of asset classes awaiting the next 14 crore investors. This event serves as your comprehensive guide to understanding and exploring various investment avenues, from traditional options like stocks and bonds to alternative assets like cryptocurrencies and real estate.
Bitcoin dominates FY24 with over 150% surge, outpacing traditional marketsBitcoin dominates FY24 with over 150% surge, outpacing traditional markets
At the start of FY 2023-24, Bitcoin was trading around $28,500. By the arrival of March 2024, its value had soared to an impressive $73,750.
Deciphering crypto sentiment: Inside the crypto Fear and Greed IndexDeciphering crypto sentiment: Inside the crypto Fear and Greed Index
The index analyzes various data points, including volatility, social media buzz, market momentum, and even Bitcoin's dominance within the crypto landscape.
Cryptocurrency Price on March 29: Bitcoin trades above $70,000; Dogecoin jumps over 9%Cryptocurrency Price on March 29: Bitcoin trades above $70,000; Dogecoin jumps over 9%
"Technical analysis shows that DOGE's performance could be attributed to a prolonged reversal, with a flattened-out bottom. We can expect a strong support around $0.15 with resistance at $0.21," said Parth Chaturvedi, Investments Lead, CoinSwitch Ventures.
Fallen crypto mogul Sam Bankman-Fried sentenced to 25 years in prisonFallen crypto mogul Sam Bankman-Fried sentenced to 25 years in prison
"There is absolutely no doubt that Mr. Bankman-Fried's name right now is pretty much mud around the world," Kaplan said of the 32-year-old California man who seemed atop the cryptocurrency universe before his businesses collapsed in November 2022, leaving customers, investors and lenders short over $11 billion, which the judge ordered him to forfeit.
For More Insights Visit ETMarkets Crypto Corner
Thanks for reading. See you next Saturday with more interesting stories and updates. Follow us on Twitter and Facebook.
Liked it? Share it with your friends
whatuphate ithate it

PS : We'd love to hear from you. Reply to this mail & share your thoughts with us.

* If you do not want to receive this mailer, please unsubscribe here.

© 2024 Times Internet Limited

Comments

Post a Comment

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh
Post a Comment
Read More

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr
Post a Comment
Read More

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side
Post a Comment
Read More